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ABSTRACT 
Congenital cognitive dysfunctions are frequently due to deficits in molecular pathways that underlie the 
induction or maintenance of synaptic plasticity.  For example, Rubinstein-Taybi syndrome (RTS) is due 
to a mutation in cbp, encoding the histone acetyltransferase CREB-binding protein (CBP).  CBP is a 
transcriptional co-activator for CREB, and induction of CREB-dependent transcription plays a key role 
in long-term memory (LTM).  In animal models of RTS, mutations of cbp impair LTM and late-phase 
long-term potentiation (LTP).  As a step toward exploring plausible intervention strategies to rescue the 
deficits in LTP, we extended our previous model of LTP induction to describe histone acetylation and 
simulated LTP impairment due to cbp mutation.  Plausible drug effects were simulated by model 
parameter changes, and many increased LTP. However no parameter variation consistent with a 
biochemical effect of a known drug class fully restored LTP. Thus we examined paired parameter 
variations consistent with effects of known drugs. A pair that simulated the effects of a 
phosphodiesterase inhibitor (slowing cAMP degradation) concurrent with a deacetylase inhibitor 
(prolonging histone acetylation) restored normal LTP. Importantly these paired parameter changes did 
not alter basal synaptic weight. A pair that simulated the effects of a phosphodiesterase inhibitor and an 
acetyltransferase activator was similarly effective. For both pairs strong additive synergism was present. 
The effect of the combination was greater than the summed effect of the separate parameter changes. 
These results suggest that promoting histone acetylation while simultaneously slowing the degradation 
of cAMP may constitute a promising strategy for restoring deficits in LTP that may be associated with 
learning deficits in RTS. More generally these results illustrate how the strategy of combining modeling 
and empirical studies may provide insights into the design of effective therapies for improving long-term 
synaptic plasticity and learning associated with cognitive disorders. 
KEY WORDS: combination therapy; Rubinstein-Taybi syndrome; computational; cognitive disorders; 
drug synergism; long-term memory 
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INTRODUCTION 
The identification of molecular lesions associated with various neurological disorders that adversely 
affect cognitive function is providing new opportunities for developing therapeutic interventions. The 
obvious first choice is to reverse the molecular lesion, or ameliorate its effects, with gene targeting 
techniques (Corti et al., 2012; Popiel et al., 2012; Rafi et al., 2012). Progress has been made, but this 
strategy has yet to provide a therapy for a human neurological disorder. A complementary approach is to 
pharmacologically manipulate an element in the biochemical pathway associated with the molecular 
lesion to compensate for loss of function (Park et al., 2014; Ehlinger et al., 2011; Guilding et al., 2007; 
McBride et al., 2005). A key challenge, however, is to identify the optimal site to target. In addition, it is 
increasingly clear from work in other fields that the targeting of multiple sites simultaneously may yield 
several advantages over targeting single sites. For example, current pharmacotherapies for cancer and 
infections often are combination therapies (Bijnsdorp et al., 2011). The majority of these therapies were 
developed by empirical, trial-and-error methods. However, there is a growing realization that a 
combination of empirical studies and modeling of intracellular signaling pathways can greatly aid the 
prediction of effective combinations of drugs (Boran and Iyengar, 2010; Severyn et al., 2011; Zhang et 
al., 2014). Combination therapies also may offer the advantages of synergism, which can allow lower 
dosages of the individual drugs to produce a desired effect (Barrera et al., 2005). Dose reductions due to 
synergism may also minimize undesirable off-target effects of the individual drugs (Zimmerman et al., 
2007).  
To examine the ways in which computational models and analyses of synergism may help to guide the 
development of therapies, we modeled aspects of the molecular network that underlies LTP, a neuronal 
correlate of memory. Several models have been developed to describe the dynamics of intracellular 
signaling pathways necessary for the induction of LTP (e.g. Bhalla and Iyengar, 1999; Hayer and 
Bhalla, 2005; Smolen et al., 2006, 2012). These models use empirical estimates of biochemical 
parameters such as cellular enzyme concentrations, Michaelis constants, and binding affinities. The 
convergence of multiple kinases and their downstream transcription factors to activate gene expression 
necessary for late LTP and the establishment of LTM, is likely to generate regions of synergism in these 
models. In the present study, we simulated effects of a molecular lesion associated with a cognitive 
disorder and LTP deficits, and attempted to predict drug combinations that could restore normal LTP 
and also exhibit synergism.  
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We selected as an exemplar Rubinstein-Taybi syndrome (RTS), a congenital disorder that is associated 
with cognitive and learning disability. RTS is associated with mutations in the gene encoding CREB 
binding protein (CBP), a histone acetyltransferase and an obligatory cofactor in the activation of 
transcription by cyclic AMP response element binding protein (CREB) (Barco, 2007; Graff and 
Mansuy, 2009; Park et al. 2014; Petrif et al., 1995; Roelfsema and Peters, 2007) (a small percentage of 
RTS is due to mutations in a related histone acetyltransferase, p300). In neurons, activation of protein 
kinase A (PKA) leads to CREB phosphorylation and consequent activation (Matsushita et al., 2001). 
Some forms of late LTP and LTM require activation of CREB (Kida, 2012; Peters et al., 2009; Pittenger 
et al., 2002) and co-activation of CBP (Korzus et al., 2004; Levenson et al., 2004). We explored whether 
our previous model describing LTP induction (Smolen et al., 2006), extended to include CBP and 
acetylation, could: a) simulate the impaired LTP seen in rodent models for RTS, b) suggest modulation 
of specific biochemical parameters as potential targets to rescue the deficit in LTP, c) identify pairs of 
parameters that are plausible drug targets and, when concurrently varied, rescue the deficit in LTP, and 
d) predict regions of synergism associated with concurrent adjustments to these parameter pairs. For 
RTS, two synergistic pharmacological manipulations were predicted to rescue LTP. 
METHODS 
The extended model of LTP induction 
Our model was constructed to simulate induction of late, protein-synthesis dependent LTP at Schaffer 
collateral synapses in the CA1 region of the hippocampus. An overview of the model, and of stimulus 
inputs, follows. Ordinary differential equations describe the dynamics of kinase activities, gene 
expression, and synaptic weight. As schematized in Fig. 1, stimuli activate three signaling pathways. 
Increased [Ca2+] activates CaM kinase II (CaMKII), Ras activation leads to activation of the ERK 
isoforms of MAPK, and increased [cAMP] activates PKA. These pathways are established as essential 
for LTP. PKA phosphorylation of an unspecified substrate is necessary to set a synaptic tag required for 
synaptic “capture” of proteins necessary for late LTP (Barco et al., 2002; Frey and Morris, 1997; 
Redondo and Morris, 2011). This PKA-sensitive synaptic tag is denoted Tag-2 (Fig. 1). Phosphorylation 
of another substrate Tag-1 by CaMKII is also necessary to set the tag (Fig. 1) as data suggests (Chen et 
al., 2001). Inhibition of ERK blocks LTP (English and Sweatt, 1997; Rosenblum et al., 2002), thus ERK 
phosphorylates another tag substrate, Tag-3. The value of a tag variable is set proportional to the product 
of the levels of Tag-1 – Tag-3. ERK is known to phosphorylate transcription factors (TFs), inducing 
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genes important for LTP (Impey et al., 1998; Waltereit et al., 2001).  In the model activated ERK 
phosphorylates a TF denoted TF-1. Activation of CREB is essential for at least some forms of late LTP. 
Inhibiting PKA attenuates CREB phosphorylation and LTP. Thus a second TF, TF-2, represents CREB 
and is phosphorylated by PKA.  
FIGURE 1  Model of key postsynaptic signaling 
pathways that underlie the induction of late LTP 
and of the mutation linked to RTS. Arrows 
indicate the sites of action of the key parameters 
used to model drug effects – kfac for 
acetyltransferase activators, kbac for deacetylase 
inhibitors, and dcAMP for PDE inhibitors. 
We model histone acetylation as necessary 
for expression of a representative gene 
product necessary for LTP, denoted GPROD. 
Acetylation is included because the essential 
CREB cofactor CBP drives acetylation and 
gene induction and is deficient in RTS. In the 
model four acetylations are needed to induce 
GPROD synthesis. Both TF-1 and TF-2 need 
to be phosphorylated to induce these acetylations. The state with four acetylations is denoted AC4 (Fig. 
1). The rate of GPROD expression is proportional to the amount of AC4.  LTP is, then, modeled as an 
increase in a synaptic weight W. The rate of increase is simply taken as proportional to the product of the 
tag variable with GPROD.   
In simulations LTP was induced by spaced tetani. Stimulus inputs were not modeled as differential 
equations, but rather as square-wave increases in synaptic Ca2+, [cAMP], and Ras activity. Four 1-sec 
tetani at intervals of 5 min were simulated. This protocol was previously used with an RTS mouse model 
(Alarcon et al. 2004). Each tetanus induced an elevation of [cAMP] with duration dcAMP.  dcAMP is a key 
model parameter because increased dcAMP was used to simulate the effect of a phosphodiesterase 
inhibitor such as rolipram.  Its control value was 1 min.  
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Further details of the model, and of stimulus parameters, are as follows. Equations and parameters are as 
in Smolen et al. (2006) except for two revisions discussed below. Separate synaptic and somatic ERK 
cascades are modeled. Equations and parameters describing these cascades are identical except that 
active somatic ERK can be imported into a nuclear compartment, with this import facilitated by PKA. 
Nuclear ERK phosphorylates TF-1. The original model assumed the second TF, TF-2, was 
phosphorylated by CaM kinase IV (CaMKIV). However, data shows that inhibiting nuclear PKA 
attenuates both CREB phosphorylation and LTP (Matsushita et al., 2001). Thus in the first revision TF-
2, which represents CREB, was assumed to be phosphorylated by PKA, and CaMKIV and nuclear 
[Ca2+] were removed from the model. The phosphorylated fraction of TF-2 is denoted by a variable 
[TF2-P] ranging from 0 to 1, and governed by the following differential equation, 
     1) 
The corresponding variable for TF-1, [TF1-P], similarly ranges from 0 to 1. TF-1 represents a TF other 
than CREB that is phosphorylated by ERK. Examples are Ets-1 or Ets-2, which when phosphorylated 
recruit CBP (Foulds et al., 2004). The combined action of TF-1 and TF-2 drives the production of a gene 
product assumed necessary for LTP, its concentration is denoted [GPROD]. 
The second revision was inclusion of histone acetylation by cooperation between CREB and CBP 
(Barrett et al., 2011). Multiple acetylations are believed to induce an “open” chromatin conformation 
allowing gene induction (Zentner and Henikoff, 2013). The model assumes four sequential acetylations, 
four differential equations and a conservation equation describe the kinetics of five histone states (0-4 
acetylations). A forward acetylation rate constant kfac is proportional to the product of the concentrations 
of [TF1-P] and [TF2-P]. A first-order rate constant for deacetylation, kbac, applies to all acetylated states. 
The equations describing histone acetylation are therefore as follows, 
( ) ( ) [ ][ ]
[ ]
[ ] ( )
( ) [ ][ ]
[ ]
[ ] ( )
fac bac
A1 A2
fac bac
A1 A2
TF1-P TF2-Pd AC1
  k AC1   k AC2
dt TF1-P K TF2-P K
TF1-P TF2-P
                     k AC0   k AC1
TF1-P K TF2-P K
= - +
+ +
+ -
+ +
    2) 
[ ] ( )phos ACT deph
d TF2-P
k PKA 1 [TF2-P] k [TF2-P]
dt
= - -
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( ) ( ) [ ][ ]
[ ]
[ ] ( )
( ) [ ][ ]
[ ]
[ ] ( )
fac bac
A1 A2
fac bac
A1 A2
TF1-P TF2-Pd AC2
  k AC2   k AC3
dt TF1-P K TF2-P K
TF1-P TF2-P
                     k AC1   k AC2
TF1-P K TF2-P K
= - +
+ +
+ -
+ +
    3) 
( ) ( ) [ ][ ]
[ ]
[ ] ( )
( ) [ ][ ]
[ ]
[ ] ( )
fac bac
A1 A2
fac bac
A1 A2
TF1-P TF2-Pd AC3
  k AC3   k AC4
dt TF1-P K TF2-P K
TF1-P TF2-P
                     k AC2   k AC3
TF1-P K TF2-P K
= - +
+ +
+ -
+ +
    4) 
( ) ( ) [ ][ ]
[ ]
[ ] ( )fac bacA1 A2
TF1-P TF2-Pd AC4
  k AC3   k AC4
dt TF1-P K TF2-P K
= -
+ +
    5) 
( ) ( ) ( ) ( ) ( )TOTAC0 AC AC4 AC3 AC2 AC1= - - - -       6) 
The rate of GPROD expression is proportional to AC4. The differential equation describing GPROD 
expression is, 
      7) 
The rate of increase of the synaptic weight W is assumed proportional to the product of the tag variable 
with the gene product and is also limited by the availability, for synaptic incorporation, of another 
protein P (Smolen et al., 2006). The differential equations for W and P are as follows, 
( )[ ] [ ][ ]W WP
PdW W  k TAG GPROD   
dt P +K τ
= -        8) 
( )[ ] [ ][ ]P P PP
PdP P  k TAG GPROD    
dt P +K
v τ= + -        9) 
Empirically and in the model, tetanic stimuli elevate [Ca2+] and [cAMP] and activate the ERK cascade. 
Basal synaptic [Ca2+] was 0.04 µM. The effect of each tetanus (100 Hz for 1 sec) was simply modeled as 
concurrent square-wave increases in [Ca2+syn], [cAMP], and Raf activation (Smolen et al., 2006). Each 
tetanus induced an increase of synaptic Ca2+ to 1 µM, for 3 s. A similar duration is suggested by data 
[ ] ( ) [ ]syn deg synbas
d GPROD
k AC4 k GPROD k
dt
= - +
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(Pologruto et al., 2004). Each tetanus induced a square-wave elevation of [cAMP] with duration dcAMP. 
Values for [cAMP] were 0.03 µM (basal) and 0.15 µM (elevated). Each tetanus also increased a rate 
constant kf,Raf for Raf phosphorylation  / activation, for 1 min. kf,Raf was 0.0075 min-1 (basal) and 0.16 
min-1 (elevated).  
Standard model parameter values in the absence of simulated drug effects are given in Smolen et al. 
(2006), with the exception of the following parameters in Eqs. 1 - 9:   
kphos = 0.12 µM-1 min-1,  kdeph = 0.03 min-1,  ksyn = 1.0 µM min-1,  kdeg = 0.01 min-1,   
ksynbas = 0.0004 min-1,  kfac = 5.0 min-1, kbac = 0.1 min-1,  KA1 = KA2 = 1.0, ACTOT = 1.0, kW = 4.0 min-1,  
τW = 100,000 min,  kP = 15.0 µM-1 min-1, vP = 0.0006 µM-1 min-1.  
The dynamics of histone acetylation and deacetylation following LTP induction have not been well 
characterized, and TF-1 is a generic transcription factor. Therefore, standard values for parameters in 
Eqs. 1 – 9 were chosen only according to the following criteria.  GPROD induction was required to have 
a similar rate of increase, and duration, to that observed for induction of immediate-early genes 
associated with LTP, such as Arg3.1/Arc (Waltereit et al., 2001; Hevroni et al., 1998). The increase in W 
was required to develop over 2 h, similar to the time course observed for induction of chemical LTP 
(Yang et al., 2002). The amplitude of the W increase was required to be similar to that observed after 
three to four 1-s duration tetani (English and Sweatt, 1997; Woo et al, 2000). The very large time 
constant for the decay of W to baseline was chosen because of observations that late LTP can persist for 
months in vivo (Abraham et al., 2002).  
The model of Smolen et al. (2006), with standard parameter values that simulate tetanic LTP, has been 
deposited in the online database ModelDB (accession # 149715).  
Numerical methods 
The simulations of Figs. 2 and 3 were integrated by two methods, forward Euler and fourth-order 
Runge-Kutta (Burden and Faires, 2005). No significant differences were observed in the results, 
therefore forward Euler was used for the remaining simulations. The time step was 40 ms. Prior to 
stimuli, model variables were equilibrated for at least two simulated days and the slowest variable, W, 
was set to an equilibrium basal value determined by the remaining variables. Programs are available 
upon request.  
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RESULTS 
Simulations of LTP and of RTS-induced LTP deficits 
Figure 2 illustrates dynamics of some key variables of 
the model, with control parameter values, in response 
to the above LTP protocol. CaMKII responds rapidly to 
each brief Ca2+ increase and deactivates in ~1 min, 
whereas synaptic ERK activity and PKA activity 
accumulate over tetani (Fig. 2A1). Nuclear import of 
ERK is driven by active PKA and after PKA 
deactivation nuclear ERK levels begin to drop. Thus 
nuclear ERK activity peaks before synaptic ERK 
activity. AC4, representing the transcription-competent 
chromatin state with four histone acetylations, peaks 
later than the kinase activities (Fig. 2A2). GPROD 
expression rises slowly.  
FIGURE 2  Model dynamics during LTP induction. A1 and 
A2 illustrate the evolution of key variables during a 
simulation of normal LTP with all parameters at standard 
values. B illustrates a simulation of LTP when a parameter 
in the model was changed to simulate the CBP deficit 
associated with RTS. (A1) Time courses of the activities of 
CaMKII, synaptic ERK, nuclear ERK, and PKA in response 
to simulated tetani delivered at 0, 5, 10, and 15 min. (A2) 
Time courses of AC4, GPROD, and W. (B) Time courses of 
AC4, GPROD, and W for the RTS model. In all panels, time 
courses of all variables, except W, are vertically scaled for 
ease of visualization. Scaling factors for CaMKII, synaptic 
ERK, PKA, nuclear ERK, AC4, and GPROD are 
respectively 0.1, 7, 40, 15, 20, and 0.7. Also note changes in 
vertical scale for y axes of A1, A2 and B. 
The synaptic weight W increases for more than 2 h 
after stimulus, consistent with data illustrating that late 
LTP takes ~2 h to develop when induced by chemical 
stimuli that bypass early protein synthesis-independent 
LTP (Ying et al., 2002). The magnitude of simulated LTP was assessed 3 h after the last tetanus, as the 
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per cent increase in W (Fig. 2A2 and 2B). Simulations using the control values for all parameters 
yielded LTP of 148% (Fig. 2A2). 
In RTS, activity of the histone acetyltransferase CBP is reduced. In the model, the activity of CBP is 
represented by a forward rate constant for histone acetylation, kfac in Eqs. 2-5. To simulate RTS kfac was 
reduced from 5.0 min-1 to 2.7 min-1. The decrease in kfac only affects histone acetylation and downstream 
processes (GPROD synthesis and LTP). Figure 2B illustrates these dynamics (note difference in scale 
from Panel A). With the lower kfac, much less AC4 accumulates, and GPROD synthesis is diminished. 
Therefore this case, denoted henceforth “RTS-basal”, has reduced tetanic LTP – only 50%, compared to 
148% in Fig. 2A2. This reduction by about two-thirds is similar to that observed in a rodent model of 
RTS, cbp heterozygous (cbp+/-) mice, (Alarcon et al. 2004). 
Systematic parameter variations to rescue impaired LTP  
The predicted effect of drugs on LTP can be examined by varying the value(s) of model parameters that 
a candidate drug might change (e.g., a drug-induced reduction or increase in enzymatic activity). A 
successful candidate parameter change should restore LTP to near its normal value (148%) while basal 
W remains near its normal value. The latter criterion was imposed because extant literature does not 
appear to report abnormal basal weights (prior to LTP) in RTS. 
Starting from the RTS-basal case (parameters at standard values except kfac = 2.7 min-1), 15 parameters 
that represent plausible drug targets were varied. These parameters were: the durations of the stimulus-
induced increases in Ca2+, kf,Raf, and cyclic AMP (cAMP); the CaMKII dissociation constant for 
Ca2+/calmodulin denoted synK , the MEK and ERK activation Michaelis constants Kmkk and Kmk, the 
Raf, MEK, and ERK inactivation rate constants kbraf, kb,mapkk, and kb,mapk; their activation rate constants 
kf,mapkk, kf,mapk, and kf,raf (basal); the PKA inactivation time constant τPKA, the histone acetylation rate 
constant kfac, and the opposing first-order rate constant for histone deacetylation in Eqs. 2-5, denoted 
kbac. The duration of stimulus-induced cAMP elevation is denoted dcAMP. Other model parameters were 
not varied because: a) they represent phosphorylation of unspecified targets, or synthesis and depletion 
of unspecified proteins, and thus cannot be targeted by specified drugs, or b) they represent overall 
synaptic weight dynamics and are not attributable to specific modeled biochemical processes. Also, 
parameters that regulate the basal level of Ca2+ were not varied because changes in basal level of Ca2+ 
would regulate too many processes to be a desirable drug target.  
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Each parameter was varied in turn by the same relative amounts, ±30%. This moderate amplitude of 
parameter change was chosen to represent plausible effects of moderate drug “doses”. LTP was 
simulated for the RTS-basal case and for these 30 parameter variations. Normal LTP was also simulated 
(parameters at standard values, kfac = 5.0 min-1). For each simulation, LTP (per cent increase of W from 
basal) was plotted vs. the basal weight (W prior to stimulus). Figure 3 illustrates the results. The red 
asterisk at (0.10, 148) denotes normal basal weight and LTP and the yellow square at (0.10, 50) denotes 
the simulated LTP deficit associated with RTS. We sought parameter variations that would restore LTP 
to near-normal values while maintaining basal synaptic weight near its normal value of 0.10.  
FIGURE 3  Variations of the magnitude of tetanic LTP with 
respect to changes in individual parameters of the model of 
Fig. 2. Starting from the RTS-basal simulation (yellow square), 
each model parameter that represents a plausible drug target is 
increased or decreased by 30%. The black squares and the 
green square illustrate the resulting LTP amplitudes vs. basal 
synaptic weights. Fifteen parameters are varied, yielding 30 
values plotted as squares. The green square represents the 
effect of increasing dcAMP by 30% (the effect of decreasing kbac 
by 30% overlaps with this square) The asterisk at (0.10, 148) 
denotes the control simulation, with normal basal weight and 
LTP. 
 
None of the single-parameter variations in Fig. 3 restored LTP to near-normal values. A 30% increase in 
the parameter dcAMP, which denotes the duration of tetanus-induced [cAMP] elevation (from 1 to 1.3 
min) increased LTP somewhat, to 69%, while leaving basal W at 0.102 (green square). This result 
plausibly corresponds to an effect of a PDE inhibitor, because inhibition of cAMP phosphodiesterase 
would prolong stimulus-induced cAMP elevation. Indeed, with cbp+/- mice, both LTP and learning have 
been improved by rolipram (Alarcon et al., 2004; Bourtchouladze et al., 2003), an inhibitor of cAMP 
phosphodiesterase 4 (PDE4) (Rose et al., 2005). By increasing cAMP levels, rolipram promotes PKA 
activation and CREB phosphorylation. A second PDE4 inhibitor, HT0712, also rescued learning 
(Bourtchouladze et al., 2003). 
A 30% reduction in the rate constant for histone deacetylation, kbac in Eqs. 2-5, gave LTP of 68%. This 
result might correspond to the effect of a deacetylase inhibitor, acting to counter the effect of a reduced 
level of CBP. Indeed, in cbp+/- mice both LTP and learning are improved by SAHA, a histone 
deacetylase inhibitor (Alarcon et al., 2004). However, no ±30% change to a single parameter restored 
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LTP to >100%, except for increasing the dissociation constant for Ca2+/calmodulin from CaM kinase II, 
synK . That increase yielded LTP of 121%, but at a cost of reducing the basal synaptic weight far below 
normal, to 0.036.  
We also simulated larger increases in dcAMP. A much larger, 100% increase elicited near-normal LTP 
(143%) while preserving basal W at 0.10 (not shown). However, such a large increase may correspond 
to a PDE inhibitor dose that would generate unacceptable side effects. With cbp+/- mice, rolipram did not 
completely restore normal LTP, although it yielded significant partial rescue (Alarcon et al., 2004). With 
our model, because single parameter changes did not give optimal results, we examined concurrent 
variations in pairs of parameters. Can LTP and basal synaptic weight both be restored by concurrent, 
moderate variations of two parameters?   
Rather than exhaustively investigating each of the 105 distinct parameter pairs for the 15 parameters, we 
used existing knowledge of biochemical pathways to eliminate variations of parameters that a priori are 
likely to correspond to unacceptable off-target effects of drugs. We did not simulate the effects of 
increases in the activation rate constants for Raf, MEK, and ERK, or decreases in their inactivation rate 
constants. This constraint was imposed because excessive activation of the ERK signaling pathway is 
associated with tumorogenesis, and drug development has therefore focused on inhibitors of this 
pathway (Roberts and Der, 2007). Similarly, decreases in the Michaelis constants for activation of ERK 
or MEK by MEK or Raf were not simulated, because these parameter changes would also increase basal 
activation of the ERK pathway. Increases in the PKA inactivation time constant τPKA were also not 
included because no small-molecule, allosteric effector of PKA has been reported to increase this 
parameter. Alterations in the CaMKII dissociation constant Ksyn, as noted above, greatly altered basal 
synaptic weight and were therefore not included. Applying these constraints left only pairs of four 
parameters to be examined. These parameters were the durations of the stimulus-induced increases in 
Ca2+ and in cAMP, and the histone acetylation and deacetylation rate constants kfac and kbac. 
Simulations with the above constraints identified two parameter combinations that may represent 
candidate targets for rescuing deficits in LTP associated with RTS. In the first parameter pair, an increase 
in the duration of stimulus-induced cAMP elevation, dcAMP, combined with a decrease in the histone 
deacetylation rate constant kbac restored LTP while preserving normal basal synaptic weight (0.10). With 
dcAMP increased by 50% and kbac decreased by 35%, LTP is 142%. These changes may respectively 
represent effects of a PDE inhibitor and a deacetylase inhibitor. In the second pair, a 50% increase in 
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dcAMP in combination with a 37% increase in the histone acetylation rate constant kfac produced, LTP 
near normal (156%) and basal synaptic weight remained at 0.1. These changes may respectively 
represent effects of a PDE inhibitor and an 
acetyltransferase activator. Because these rescues 
appeared encouraging, we examined whether 
these pairs of parameters exhibit synergism. 
Qualitatively, synergism implies that drugs 
reinforce each other such that their effect in 
combination exceeds the prediction given by 
adding their separate effects (Bijnsdorp et al., 
2011). 
Strong additive synergism occurs for both 
candidate parameter pairs. 
We started with kfac = 2.7 min-1 (the RTS-basal 
case), and simulated parameter-response (PR) 
curves for (dcAMP, kbac) (Fig. 4A). The response 
measure was percent LTP.  
FIGURE 4  Simulated rescue of LTP deficits.  (A) 
Parameter-response (PR) curves for the individual 
parameters, with maximal parameter changes chosen 
such that the magnitude of LTP is near normal (i.e., so 
that the simulated LTP defect is overcome). The green 
asterisk on the upper curve corresponds to a dcAMP 
increase to 2.0 min (used in B), the blue asterisk on 
the lower curve corresponds to a kbac decrease to 0.03 
min-1 (used in B). For each parameter, to construct its 
PR curve, LTP was simulated at 51 equally spaced 
parameter increments including the endpoints. (B) 
Additive synergism is seen over the entire parameter 
range when dcAMP is varied from 1.0 min to a maximum of 2.0 min, and kbac is concurrently varied from a 
minimum of 0.03 min-1 to 1.0 min-1. To construct these curves, LTP was simulated at 51 equally spaced parameter 
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increments including the endpoints. (C) Additive synergism is also seen when dcAMP is varied from 1.0 min to a 
maximum of 2.0 min and kfac is concurrently varied from a maximum of 4.7 min-1 to its standard, RTS-basal value 
of 2.7 min-1. 
The PR curves of Fig. 4A are similar to drug dose-response curves. They delineate ranges of variation of 
the histone deacetylation rate constant (kbac), and of the duration of stimulus-induced elevation of cAMP 
(dcAMP), that give substantial, up to near-saturating, enhancement of the response. These are the ranges 
over which useful synergism might be expected to occur.  Maximal parameter changes from control 
values, at the right endpoints of the curves, were chosen such that the magnitude of LTP was in the 
normal range (i.e., so the simulated RTS defect was overcome). These are large, not moderate, changes 
from control values. The dcAMP curve is fairly linear up to a saturated plateau. The kbac curve shows 
nonlinearity, acceleration to a peak followed by a decline. This nonlinearity occurs because kbac affects 
multiple sequential deacetylation reactions. 
We chose an intuitive measure of synergism. Additive synergism occurs whenever, given fixed doses of 
drugs A and B, the response to A and B combined exceeds the sum of the responses to A alone and to B 
alone. For a model’s prediction of additive synergism to be of therapeutic interest, the simulated 
synergism should be robust in that it should persist over a range of variation of model parameters. We 
implemented a novel, relatively simple way of visualizing whether robust additive synergism is present 
for a parameter pair. This method is illustrated in Figs. 4B-C.  As the parameters are concurrently varied, 
two curves are constructed, denoted “combined effect” and “summed effect”. 
For each of these curves in Fig. 4B, the right endpoint corresponds to dcAMP increased above basal while 
kbac remained at basal (high “PDE inhibitor”, zero “deacetylase inhibitor”), and the left endpoint 
corresponds to kbac decreased below basal while dcAMP was at basal (high “deacetylase inhibitor”, zero 
“PDE inhibitor”). From the PR curves, these endpoint values of dcAMP and kbac were chosen such that the 
corresponding enhancements of LTP were substantial, to normal values. These endpoint values, of 2.0 
min for dcAMP  and 0.03 min-1 for kbac, correspond respectively to 144%  LTP on the dcAMP PR curve in 
Fig. 4A (green asterisk) and to 153% LTP% on the kbac PR curve (blue asterisk). On the synergism 
curves (Fig. 4B), from left to right, dcAMP and kbac increase linearly. Thus with exception of the 
endpoints, all points are associated with a concurrent dcAMP increase above its standard value and kbac 
decrease below its standard value. For each concurrent increase and decrease, the corresponding point 
on the “combined effect” curve, directly above, provides the amplitude of the simulated LTP. The 
corresponding point on the “summed effect” curve is, in contrast, the LTP amplitude expected if the 
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individual LTP enhancements due to the dcAMP increase and kbac decrease simply added. This LTP 
amplitude is calculated from two simulations in which each of these parameter changes are applied 
separately. The resulting LTP enhancements are added together and then added to the LTP obtained with 
all parameters at standard values used to simulate the LTP deficit. Additive synergism is present when 
the “combined effect” curve lies above the “summed effect” curve, which is the case in Figs. 4B (red 
vertical bar). Therefore, additive synergism is robust in the parameter range illustrated in Fig. 4B. 
Throughout this range, the basal synaptic weight remained within 15% of its control value of 0.10. 
We also found synergism for the second parameter pair that rescued LTP, an increase in dcAMP combined 
with an increase in kfac. For these curves, the right endpoint corresponds to dcAMP increased to a 
maximum while kfac remained at its RTS-basal value of 2.7 min-1 (high “PDE inhibitor”, zero “acetylase 
activator”), and the leftmost point to kfac increased to a maximum while dcAMP was at basal (high 
“acetylase activator”, zero “PDE inhibitor”). Relatively large maxima were chosen for both dcAMP (2.0 
min, on the saturated plateau of the PR curve in Fig. 4A) and kfac (4.7 min-1), in order that the resulting 
combined effect curve simulated full restoration of LTP (from 50% in the RTS-basal case to ~140-
160%). Strong additive synergism was simulated (Fig. 4C) and was robust through this parameter range. 
Throughout the range, basal synaptic weight remained within 18% of the control value of 0.10. 
DISCUSSION 
A model of some of the key biochemical pathways required for the induction of LTP could simulate 
impaired LTP seen in rodent models of RTS and suggest modulation of specific biochemical parameters 
as potential targets to rescue this LTP deficit. Moderate changes in single parameters failed to rescue 
LTP, but rescue was produced by moderate simultaneous changes in two pairs of parameters that are 
plausible targets of currently available drug types. Furthermore, the model proved useful in predicting 
regions of synergism illustrated with concurrent adjustments to these parameter pairs (Fig. 4). The 
model is a simplification of the complex processes underlying LTP and memory and of the effects of a 
CBP deficit. Nonetheless we believe the simulations of LTP rescue and of additive synergism in Fig. 4 
suggest candidate drug combinations for rescue of LTP deficits that, based on rodent models, may 
correlate with cognitive deficits seen in RTS. One drug combination would use a PDE inhibitor and a 
deacetylase inhibitor (DAI), the second would replace DAI by an acetyltransferase activator. 
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PDE inhibitors and DAIs have been tested individually in rodent models of RTS (Alarcon et al., 2004; 
Bourtchouladze et al., 2003) and DAIs have been suggested as candidate therapeutics for several human 
disorders, including RTS (Kazantsev and Thompson, 2008). Rolipram has not proved suitable for human 
therapy due to gastrointestinal side effects (Scott et al., 1991), but new PDE4 inhibitors, such as HT0712 
and oglemilast (Giembycz, 2008; MacDonald et al., 2007), are undergoing clinical trials. Several small-
molecule activators of histone acetyltransferase activity have been reported. The compound CTPB 
activates p300 (Mantelingu et al., 2007), an acetyltransferase and transcriptional co-activator that has 
similar structure to CBP (Marmorstein and Trievel, 2009). However, to our knowledge, an 
acetyltransferase activator has yet to be tested in animal models of either RTS or other cognitive 
disorders. Also, no drug combinations appear to have yet been tested in an animal RTS model, although 
Alarcon et al. (2004) previously suggested that combining a drug similar to rolipram with a DAI might 
consistute a candidate therapy for RTS. Such tests could determine whether, as our model suggests, 
rescue of LTP and learning might be achieved with substantially lower doses of the individual drugs, 
possibly ameliorating side effects. 
We believe that the use of models to identify concurrent parameter changes that rescue LTP deficits, or 
other phenotypes, can substantially increase the efficiency of subsequent empirical studies by 
prioritizing which drug combinations to test first, and at which dose ranges. In this study, simulations 
combined with inductive reasoning not only identified two promising parameter pairs out of >100 
possible pairs, but also suggested, for both pairs, concurrent parameter variations for which additive 
synergism was maximized and LTP was simultaneously restored to near-normal values. In Fig. 4B (for 
dcAMP and kbac) and Fig. 4C (for dcAMP and kfac) the variations with maximal synergism are near dcAMP = 
1.5. We note that for Fig. 4C, the combined-effect curve is concave down with the center higher than the 
endpoints. This parameter pair therefore exhibits additional synergism, termed strong nonlinear blending 
synergism (Peterson and Novack, 2007). Subsequent empirical studies might initially focus on these 
pairs and develop empirical descriptions of dose-effect relationships that allow translation of parameter 
changes in this range to drug doses.  
In addition to combination drug therapies, a related type of synergism that may prove useful in treating 
cognitive disorders could occur between drugs and optimized training protocols. One study (Zhang et 
al., 2011) illustrated that, for a simple form of learning, modeling of the dynamics of biochemical 
interactions in sensory neurons successfully predicted a set of interstimulus intervals (ISIs) between 
repeated stimuli that enhanced the formation of LTM. Experiments verified that the predicted stimulus 
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spacing increased long-term synaptic facilitation (LTF, a correlate of LTM). A subsequent study (Liu et 
al., 2013) impaired LTF between sensory and motor neurons by knocking down CBP expression – an in 
vitro analogue of the molecular lesion responsible for RTS. Then, an extended variant of the model of 
Zhang et al. (2011) was used to predict a rescue protocol, consisting of a set of variable ISIs between 
repeated stimuli that would restore LTF to normal levels. Experiments verified that this protocol rescued 
LTF. These results suggest that in mammals, training protocols with variable intervals could be 
predicted, with the help of models, to enhance or restore learning. A logical extension of these results 
will be to use the model to predict the effects of combining drugs with improved training protocols. 
Additive synergism between drugs and training could be assessed within this paradigm.  
A limitation of such combined strategies will be the incompleteness of models describing LTP induction 
combined with empirical uncertainties in parameter values. In model construction, parameter values are 
generally not all available from a single experimental preparation, or a single species of animal. Instead, 
data from several types of preparations (e.g. slice and cell culture) and animals (e.g. rodents and 
primates) need to be used (Bhalla and Iyengar, 1999; Hayer and Bhalla, 2005; Smolen et al., 2006; 
Smolen et al., 2012). Molecule copy numbers per neuron are also difficult to determine for enzymes or 
other macromolecules involved in LTP. Although these limitations are substantial, we believe that the 
potential benefits of this strategy that combines modeling and empirical studies are considerable.  
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